Peripheral Blood Stem Cell Transplantation In The Treatment Of Cirrhosis Clinical Applications(a Report Of Four Cases)

Background: The treatment of cirrhosis of the liver has become one ofthe focus of attention of the world, with advanced cirrhosis often appearmore serious complications are extremely hazardous, aggressive medicaltreatment can not put it into reverse. Currently, the most effective treatmentfor cirrhosis is liver transplantation, can fundamentally improve the liverfunction, improve the patient’s quality of life and prolong survival ofpatients, but due to lack of donor liver source, the high cost of surgery thatmay occur after transplantrejection, long-term use of immunosuppressiveagents, limiting their wider application to carry out. Stem cells are a classof self-replicating and self-renewal capacity of pluripotent cells, the cellscan differentiate into a variety of cell lines, i.e., cardiac muscle, liver,cartilage, fat, muscle, nerve cells, etc. may be formed in the type underinducing conditions. In recent years, stem cell transplantation for thetreatment of cirrhosis of the liver has brought new hope.Objective: To investigate peripheral blood stem cell transplantation inthe treatment of decompensated cirrhosis research methods and clinicaleffect.Methods: November2010to July2011at the Dalian Medical UniversityFirst Affiliated Hospital4patients with liver cirrhosis, hepatitis B patientswith decompensated cirrhosis in3cases, autoimmune liver diseasedecompensatedcirrhosis patients, aged31-67years, mean age of44yearsold. Collected after granulocyte colony-stimulating factor (G-CSF) tomobilize peripheral blood stem cells, the hepatic artery autologousperipheral blood stem cell transplantation for treatment. Comparisonbetween the4patients,3cases of hepatitis, cirrhosis with autoimmune liver disease cirrhosis patients, three cases of hepatitis in patients with cirrhosiscompared with pre-transplant and post-transplant1month,3months,6months liver function, liver fibrosis, radiographic parameters are compared,and any adverse reactions and clinical symptoms observed aftertransplantation.Results: patients with peripheral blood stem cell collection, stem celltransplantation and postoperative hepatic artery without fever, infection,gastrointestinal bleeding, hepatic encephalopathy, gastrointestinalsymptoms and other adverse reactions occur, autologous peripheral bloodstem cell transplantation in a month,3months,6months, anorexia, fatigue,loss of appetite, abdominal distension and other symptoms graduallyimproved to varying degrees. Liver function: AST, ALT than beforetransplantation decreased gradually; CHE, ALB increased gradually thanbefore transplantation; the PT than pre-transplant gradually decreased.Liver fibrosis: hepatitis patients with cirrhosis HA, PC-III, C-IV LN thanautoimmune liver cirrhosis decline more obvious; HA, PC-III than C-IV, LNdecreased significantly. Radiographic parameters: Portal vein diameter andspleen anteroposterior diameter, transverse diameter, no significant changein vertical diameter than before transplantation.Conclusion: peripheral blood stem cell transplantation for the treatmentof patients with decompensated cirrhosis patients can improve clinicalsymptoms and liver function, liver fibrosis, treatment safety and sideeffects.